Figure 1 (Pemetrexed Fig1)
Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 55150-381
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 55150-381). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Package Label-principal Display Panel- 100 mg Per Vial (Container Label)
This is a description of a medication called Pemetrexed Disodium stored in vials equivalent to 100mg Pemetrexed. The vial also contains 106mg Mannitol, along with Hydrochloric acid and/or Sodium Hydroxide to adjust PH, if necessary. It can be stored at 25°C, with excursions advised at 15-30°C. However, further details can be found in the provided package insert for the storage of reconstituted and infusion 100mg per vial solutions. The medication is manufactured in India for AuroMedics Pharma LLC and is only for intravenous use. Caution is recommended since it is a Cytotoxic agent and any unused portion should be discarded.*
Package Label-principal Display Panel- 100 mg Per Vial (Container Carton)
This is a description of a medication called "Pemetrexed for Injection, USP" that comes in vials of 100 mg each. It is administered intravenously and is a cytotoxic or anti-cancer drug. To reconstitute, 4.2 mL of 0.9% Sodium Chloride Injection is needed to create a solution containing 25 mg/mL pemetrexed. The reconstituted solution must be further diluted before use. The usual dosage is provided on the package insert. The medication must be stored at controlled room temperature and refrigerated after reconstitution. The stopper of the vial is not made with natural rubber latex. This product is distributed by AuroMedics Pharma LLC in E. Windsor, NJ and is made in India.*
Package Label-principal Display Panel- 500 mg Per Vial (Container Label)
Pemetrexed is a cytotoxic agent available in single-dose vials containing 500mg of pemetrexed disodium and 500mg of mannitol. It is intended for intravenous use only and any unused portion should be discarded. The pH of the powder may be adjusted using hydrochloric acid and/or sodium hydroxide. It should be stored at a temperature range of 15 to 30°C. The drug is manufactured in India for AuroMedics Pharma LLC in E. Windsor, NJ 08520. Refer to the package insert for storage of reconstituted and infusion solutions.*
Package Label-principal Display Panel- 500 mg Per Vial (Container Carton)
This is a description of Pemetrexed, a cytotoxic agent used as an injection in the treatment of certain types of cancer. It comes in a single-dose vial with 500 mg per vial. The vial contains pemetrexed disodium equivalent to 500 mg pemelrexed and mannitol. To reconstitute, 20 mL of 0.9% Sodium Chloride Injection is added. After reconstitution, the solution must be further diluted before use. The usual dosage is given in the package insert. It must be administered within 24 hours after initial reconstitution. Unused portions must be discarded. The powder should be stored at 25°C, and reconstituted and infusion solutions refrigerated at 2 to 8°C. This product is distributed by AuroMedics Pharma LLC and made in India.*
Package Label-principal Display Panel- 1,000 mg Per Vial (Container Label)
This is a description of a medication called Pemetrexed, available in a vial containing 1,000 mg of the active ingredient along with 1,000 mg of mannitol. The hydrochloric acid and sodium hydroxide are added to adjust the PH if needed. It is recommended to store the powder at controlled room temperature, and a caution of being a cytotoxic agent can be found on the label. The medication is for intravenous use only, and the unused portion code is TSDRUGS24/2015. Instructions for storage and use can be found in the package insert.*
Package Label-principal Display Panel- 1,000 mg Per Vial (Container Carton)
This is a product description for Pemetrexed, a cytotoxic agent for intravenous use. The product is a powder stored in a vial with 1000mg of pemetrexed disodium. To reconstitute, 40 mL of a specific sodium chloride injection should be added and used within 24 hours. The product must be further diluted before use. The product should be stored at controlled room temperature and reconstituted and infusion solutions should be refrigerated. The vial stopper is not made with natural rubber. The dosage should be determined based on the package insert for dosage guidance. The product is distributed by AuroMedics Pharma LLC and made in India, with a code of TS/DRUGS/24/2015.*
Figure 2 (Pemetrexed Fig2)
This is a graph showing the survival probabilities over time for two different chemotherapy treatments, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The x-axis shows the survival time in months and the y-axis displays the survival probability. The line graph shows that the survival probability for PC is higher than GC at the beginning, but the two treatments have similar survival probability later on. The numbers on the right represent the count of patients who are "at risk" of survival (continuing the treatment) at each time point for both treatment groups.*
Figure 3 (Pemetrexed Fig3)
This is a table with information about the survival probability of patients treated with two different chemotherapy treatments: Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The table shows the number of patients at risk and their survival time in months for each treatment. It also illustrates the survival probability values over time for the two treatments.*
Figure 4 (Pemetrexed Fig4)
Figure 5 (Pemetrexed Fig5)
This table shows the survival probability for patients treated with pemetrexed vs placebo, along with the number of patients at risk in each group. The survival time in months is also included in the table.*
Figure 6 (Pemetrexed Fig6)
Not available.*
Figure 7 (Pemetrexed Fig7)
This appears to be a graph showing the survival time in months for patients treated with Pometrexed compared to those who received a Placebo. The numbers indicate the number of patients at risk at different time intervals.*
Figure 8 (Pemetrexed Fig8)
Figure 9 (Pemetrexed Fig9)
Chemical-structure (Pemetrexed Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
